論文・技術情報追加のお知らせ

1. Investigating drug-induced urinary retention: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024.

薬剤による尿閉（DIUR）のリスクを特定し、対策を提案する研究

対象DB：FAERS

2. Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system.

抗体薬物複合体（ADC）は、特にチューブリン結合型で末梢神経障害のリスクが高い

対象DB：FAERS

3. Safety analysis of fluoroquinolone drugs in elderly patients over 65 based on FAERS.

高齢者のフルオロキノロン系薬剤は、心疾患や精神障害のリスクが異なる

対象DB：FAERS

4. Safety analysis of quinolones use in minors-based on the FAERS database.

小児におけるキノロン系薬剤の有害事象は年齢により異なる

対象DB：FAERS

5. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.

抗肥満薬の消化器系有害事象に関する分析、オルリスタットが最も関連性が高い

対象DB：FAERS

6. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study.

GLP-1受容体作動薬は自殺、脱毛、誤嚥の報告が多いが、明確なシグナルは確認されず

対象DB：EudraVigilance,FAERS,VigiBase

7. A national analysis of systemic adverse events of beta-blockers used for glaucoma therapy.

緑内障治療のβ遮断薬で重篤な全身副作用が稀に報告

対象DB：FAERS

8. A real-world pharmacovigilance study of KRAS G12C mutation inhibitors based on the food and drug administration adverse event reporting system.

ソトラシブとアダグラシブの安全性を評価し、主要な副作用を特定

対象DB：FAERS

9. Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment.

シクロスポリン治療中に脱毛が報告された症例を分析

対象DB：FAERS

10. Toxicity profiles associated with EGFR-TKIs combined with angiogenesis inhibitors in non-small cell lung cancer: an epidemiological surveillance analysis of the FDA adverse event reporting system.

EGFR-TKIと抗血管新生剤併用のNSCLC治療で、多様な副作用が確認された

対象DB：FAERS

11. ORENITRAM's decadal journey: unveiling safety profiles and adverse event through a real-world pharmacovigilance study of FAERS events.

ORENITRAMで肺水腫や心室細動などの重篤な副作用が報告された

対象DB：FAERS

12. Semaglutide-associated kidney injury.

セマグルチド使用で急性間質性腎炎と足細胞障害が報告された

対象DB：FAERS

13. High-risks drug adverse events associated with Cetirizine and Loratadine for the treatment of allergic diseases: A retrospective pharmacovigilance study based on the FDA adverse event reporting system database.

セチリジンはロラタジンより神経・精神系の副作用リスクが高い

対象DB：FAERS

14. A real-world pharmacovigilance study of esketamine nasal spray.

エスケタミン鼻スプレーの新たな副作用シグナルを発見

対象DB：FAERS

15. Safety assessment of basiliximab using real-world adverse event data from the FDA Adverse Event Reporting System Database: A retrospective observational study.

バジリキシマブの副作用を分析し、新たな反応も報告

対象DB：FAERS

16. Toxicity profiles of immune checkpoint inhibitors in nervous system cancer: a comprehensive disproportionality analysis using FDA adverse event reporting system.

神経系癌患者の免疫関連副作用を分析

対象DB：FAERS

17. Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.

抗腫瘍剤による腫瘍崩壊症候群のリスクを評価

対象DB：FAERS

18. Comprehensive understanding of the adverse effects associated with temozolomide: a disproportionate analysis based on the FAERS database.

テモゾロミドの副作用に関する新たな知見を発見

対象DB：FAERS

19. Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database.

デクスメデトミジンの副作用を分析し、新たな副作用も特定

対象DB：FAERS

20. Assessment of Cardiovascular Events Caused by New-Generation Androgen Receptor Pathway Inhibitors Used for Prostate Cancer: A Real-World Study in Japan.

エンザルタミドはアビラテロンより心血管イベントのリスクが低い

対象DB：FAERS

21. Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire.

IBD治療におけるステロイドの副作用は頻繁で、患者のQOLに影響

対象DB：FAERS,VigiBase

22. Adverse events associated with Atogepant: a FAERS-based pharmacovigilance analysis.

アトゲパンと関連する副作用を特定し、安全性向上に寄与

対象DB：FAERS

23. Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024).

LAIV接種後の失神は稀だが、一部で負傷や緊急評価が必要

対象DB：FAERS,VAERS

24. Analysis of anticholinergic drugs associated with aspiration pneumonia using the Japanese adverse drug event report database: Supplementary insights from a scoping review.

抗コリン薬は高齢者で誤嚥性肺炎のリスクを高める可能性あり

対象DB：JADER

25. Association of Clopidogrel with Interstitial Lung Disease: Gaining Insight Through the Japanese Pharmacovigilance Database.

クロピドグレルは予期しない副作用が多く、プラスグレルとは異なる副作用プロファイルがある

対象DB：JADER

26. Clinical and radiological pattern of olaparib-induced interstitial lung disease.

オラパリブ誘発性肺疾患はまれですが、3か月以内に発症することがあり、治療には薬剤中止が推奨される

対象DB：VigiBase

27. Unveiling the association between fluoroquinolones and aortic diseases using real-world database analysis and pharmacological experiments.

フルオロキノロンは大動脈疾患のリスクを有意に増加させない

対象DB：VigiBase

28. A pharmacovigilance study on clinical factors of active vitamin D(3) analog-related acute kidney injury using the Japanese Adverse Drug Event Report Database.

活性型ビタミンD3製剤はAKI発症と関連があり、特に高齢者に注意が必要

対象DB：JADER

29. The Evaluation of Hospitalist Care for Patients with Aspiration Pneumonia Using Risk-adjusted Performance Indicators Developed from a Nationwide Inpatient Database.

多層予測モデルを用いて誤嚥性肺炎の医療の質を評価

対象DB：DPC

30. Usefulness and caveats of real-world data for research on hypertension and its association with cardiovascular or renal disease in Japan.

レセプトデータは高血圧研究で有用だが、偏りや精度に注意が必要

対象DB：DeSC,NDB

31. Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan-A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform.

フィネレノン使用者で高カリウム血症の発生率は低く、安全性が示唆された

対象DB：MDV

32. Pulmonary fibrosis and lung cancer: an analysis of the Clinical Practice Research Datalink linked to the National Cancer Registration Dataset.

肺癌患者では肺線維症の診断率が高く、生存率は低い

対象DB：CPRD

33. Primary liver cancer risk and mortality in patients with alcohol-related cirrhosis in England and Denmark: observational cohort studies.

ALD肝硬変患者の肝癌リスクと死亡率は英・デンマークで同等

対象DB：CPRD

34. Incidence of new fractures in older patients with osteoporosis receiving biosimilar teriparatide or reference products: A retrospective cohort study.

バイオシミラーテリパラチドは、骨折と骨肉腫のリスクが参考製品と同等で、安全かつ効果的

対象DB：DeSC